Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Hyper-CL: reducing effectively corneal edema

Search Title by author or title

Session Details

Session Title: Cornea Medical II

Session Date/Time: Tuesday 13/09/2016 | 08:00-10:30

Paper Time: 10:24

Venue: Hall C3

First Author: : R.Diaz Céspedes SPAIN

Co Author(s): :    S. Garcia-Delpech   A. Hervás   P. Udaondo   E. Sanz Marco   W. Furlan   D. Salom     

Abstract Details

Purpose:

Hyper osmotic Contact Lens (Hyper-CL) is an effective non-surgical treatment of corneal edema. It is a unique contact lens that creates a cavity above the center of the cornea. that cavity can store hypertonic drops for long duration and by that, extract fluid by osmosis from the cornea.The aim of this study is to evaluate the efficacy and safety of the Hyperosmotic Contact Lens (Hyper-CL) in the treatment of corneal edema.

Setting:

The study was done at AIKEN. Valencia,Spain

Methods:

We performed Hyper-CL (Hioxifilcon D) contact lens for therapeutic use to protect corneal surface and to relieve corneal pain in 20 patients with acute and chronic ocular pathologies such as bulls keratopathy, corneal erosions, entropion, corneal edema and corneal dystrophies. We prescribed the lenses for daily use with removal for cleaning and disinfection prior to reinsertion. In order to increase the effect, we used hypertonic solution.

Results:

In all cases, Hyper-CL improved significantly vision and relieved pain in all the clinical situations. All the patients with chronic edema who were treated showed significant improvement in vision acuity and pain relief was observed in a few hours.

Conclusions:

Hyper-CL, the innovative, patent-protected solution to the complications of visual loss and pain secondary to corneal edema has proven success in relieving corneal edema.

Financial Disclosure:

NONE

Back to previous